10 | LEBRIKIZUMAB PROVIDES CLINICALLY MEANINGFUL RESPONSE IN FACE AND HANDS IN ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: ADHOPE 1 STUDY: L. Stingeni1, C. Vestergaard2, J. Seneschal3|4, S. Weidinger5, A. Wollenberg6|7|8, A. Irvine9, H. Agell10, J. Valls Bancells10, V. Sapena10, D. Thaçi7 | 1Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; 2Department of Dermatology and Venerology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Dermatology, University of Bordeaux, Bordeaux, France; 4Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-André, Bordeaux, France; 5Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany; 6University Medical Center of Augsburg, Augsburg, Germany; 7Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; 8Department of Dermatology and Allergology, LMU Hospital, Munich, Germany; 9Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; 10Almirall S.A., Barcelona, Spain. Dermatol Reports [Internet]. 2026 Sep. 24 [cited 2026 Sep. 24];18(s1). Available from: https://journals.pagepress.net/dr/article/view/11077